AstraZeneca Pharma India Limited had vide its letter dated August 16, 2018 informed the receipt of marketing authorization for Olaparib (Lynparza) 100mg and 150 mg tablets which was also indicated for the treatment of patient with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. The company has now received permission for voluntary withdrawal of the above-mentioned indication of Olaparib (Lynparza) 100mg and 150 mg tablets from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.